OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH347662D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson's diseases. OptiNose develops powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company also develops exhalation delivery system technology used for the treatment of neurological or psychiatric disorders, and central nervous system disorders. It has operations in the US, Norway and the UK. OptiNose is headquartered in Yardley, Pennsylvania, the US.

OptiNose US Inc (OPTN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 10

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OptiNose US Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

OptiNose Raises USD37 Million in Series D Financing 12

Optinose Raises USD30 Million in Venture Financing 13

Private Equity 14

Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 14

Partnerships 16

OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 16

Equity Offering 17

Optinose Raises USD55.6 Million in Public Offering of Share 17

Optinose to Raise Funds through Public Offering of Shares 19

OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 20

OptiNose Raises USD138 Million in IPO of Shares 21

Debt Offering 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23

OptiNose US Inc-Key Competitors 24

OptiNose US Inc-Key Employees 25

OptiNose US Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

May 14, 2018: Optinose Announces First Quarter 2018 Financial Results 27

Mar 13, 2018: Optinose Announces Fourth Quarter and Full Year 2017 Financial Results 29

Nov 27, 2017: Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights 31

Corporate Communications 33

Feb 22, 2018: Optinose names Sandra L. Helton as Director and Chairperson of the Company's Audit Committee 33

Feb 09, 2017: OptiNose appoints chief legal officer 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Tables

OptiNose US Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 10

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OptiNose Raises USD37 Million in Series D Financing 12

Optinose Raises USD30 Million in Venture Financing 13

Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 14

OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 16

Optinose Raises USD55.6 Million in Public Offering of Share 17

Optinose to Raise Funds through Public Offering of Shares 19

OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 20

OptiNose Raises USD138 Million in IPO of Shares 21

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23

OptiNose US Inc, Key Competitors 24

OptiNose US Inc, Key Employees 25

OptiNose US Inc, Subsidiaries 26

List of Tables

OptiNose US Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 10

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OptiNose Raises USD37 Million in Series D Financing 12

Optinose Raises USD30 Million in Venture Financing 13

Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 14

OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 16

Optinose Raises USD55.6 Million in Public Offering of Share 17

Optinose to Raise Funds through Public Offering of Shares 19

OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 20

OptiNose Raises USD138 Million in IPO of Shares 21

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23

OptiNose US Inc, Key Competitors 24

OptiNose US Inc, Key Employees 25

OptiNose US Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

OptiNose US Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18103
Site License
USD 500 INR 36205
Corporate User License
USD 750 INR 54308

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com